Interferon alpha for the adjuvant treatment of cutaneous melanoma

Mocellin, Simone; Lens, Marko; Pasquali, Sandro; Pilati, Pierluigi; Chiarion-Sileni, Vanna

doi:10.1002/14651858.cd008955.pub2

Cited by 139 publications

(98 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Meta-analysis of studies assessing the survival benefit of adjuvant interferon alpha in adult populations showed improved survival at 5 years and a 9% risk reduction. 25 Nevertheless, this would not be expected to improve DSS to 100% as noted in our study. Instead, we propose the increase in survival may also be ref lective of over-diagnosis of SSM because patients with benign lesions would have 100% DSS.…”

Section: Discussionmentioning

confidence: 51%

Superficial Spreading Melanomas in Children

Allan

Ovadia

Tashiro

et al. 2015

Annals of Plastic Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 51%

Superficial Spreading Melanomas in Children

Allan

Ovadia

Tashiro

et al. 2015

Annals of Plastic Surgery

View full text Add to dashboard Cite

show abstract

“…Adjuvant interferon alpha treatment in melanoma fulfills the criteria for a therapeutic approach for which such a biomarker would be highly desirable: Several studies support the therapeutic efficacy in terms of disease-free survival and to a lower extent overall survival [16]–[21]. This potential benefit is counteracted by the fact that interferon alpha has to be taken for many months and is often associated with side effects that affect patients' quality of life.…”

Section: Discussionmentioning

confidence: 99%

IL28B Polymorphism Cannot Predict Response to Interferon Alpha Treatment in Patients with Melanoma

et al. 2014

View full text Add to dashboard Cite

BackgroundRecent genome-wide association studies revealed the rs12979860 single nucleotide polymorphism (SNP) of the IL28B gene (CC genotype) to be the strongest pre-therapeutic predictor of therapy response to interferon alpha in patients with chronic hepatitis C infection. The favorable CC genotype is associated with significantly higher rates of sustained virologic response. No data exist on the role of IL28B polymorphism in interferon therapy of diseases other than viral hepatitis.MethodsA retrospective study involving 106 patients with melanoma who received low- or high-dose interferon therapy was performed. The CC and non-CC genotype of IL28B rs12979860 SNP were correlated with progression-free and overall survival.Results44 (41.5%) patients were CC and 62 (58.5%) non-CC. There was no statistically significant difference in age at diagnosis, melanoma type or localization, Breslow level or AJCC stage between CC and non-CC patients. During the observation period (6.43±4.66 years) disease progression occurred in 36 (34%) patients after 5.5±4.3 years. 43.2% (19) of patients with CC and 27.4% (17) of patients with non-CC genotype were affected (p = 0.091). Disease progression was more frequent in patients on high dose interferon therapy and with a worse AJCC stage.ConclusionIn contrast to classical risk factors like tumor thickness and clinical stage, IL28B polymorphism was not associated with progression-free or overall survival in patients with melanoma treated with interferon alpha.

show abstract

“…This therapy has many side-effects that greatly impact quality of life and the overall survival benefit is very small. 16 More recently, the targeted and immune checkpoint therapies that are useful in metastatic disease are being evaluated in the adjuvant setting. Ipilimumab reduces relapse rates compared with placebo at one, two and three years.…”

Section: Other Treatments For Advanced Diseasementioning

confidence: 99%